Researchers analyze how e-cigarette particle size, deposition change with different factors

Researchers analyze how e-cigarette particle size, deposition change with different factors

E-cigarette use is rising, particularly among young adults and teens. Recent illnesses and deaths attributed to vaping have caused intense scrutiny of the chemicals in e-liquids and vapor, but little is known about the size of vaping particles and their deposition patterns in human airways. Now, researchers reporting in ACS' Chemical Research in Toxicology have analyzed how e-cigarette particle size and deposition change with factors such as device power, e-liquid composition and vaping practices. Unlike regular cigarettes, which burn tobacco to produce smoke, e-cigarettes are battery-powered devices that heat an e-liquid to form an aerosol, which the user inhales. E-liquids typically contain nicotine, flavoring agents and a base material, such as vegetable glycerin or propylene glycol. Because e-cigarettes do not combust tobacco, they are thought to be less harmful to human health than regular cigarettes. However, actual health risks are not well understood. Therefore, Qingyu Meng and colleagues wanted to investigate the particles produced by vaping, which typically consist of liquid droplets of the base material, and how they might be deposited in human airways. Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More